StockData

Krystal Biotech vs Vericel

KRYS and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRYS and VCEL compare

Krystal Biotech is the larger company, worth 3.0 times as much as Vericel ($8.8B against $2.9B).

On earnings, Krystal Biotech is cheaper: it trades at 37.3× trailing earnings, against 137× for Vericel.

Vericel grew revenue faster over the last twelve months (23.0% versus 22.6% for Krystal Biotech).

Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with 7.9% at Vericel.

Vericel scores higher on the StockData Score (14 against 11 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRYSVCEL
Size and price
Market cap$8.8B$2.9B
Share price$297.90$57.48
Change, 1 year48.1%44.3%
Change, 5 years648%50.0%
Beta (5Y)1.01−0.01
Employees295398
StockData Score
Total score1114 (better)
Valuation score1 (better)0
Growth score14 (better)
Performance score34 (better)
Health score66
Dividend score00
Valuation
P/E37.3× (better)137×
P/S20.0×9.6× (better)
P/B6.5× (better)8.0×
EV/EBITDA40.3× (better)89.3×
P/FCF34.2× (better)47.7×
FCF yield2.9% (better)2.1%
Fair value$196.32$13.52
Margin of safety−51.7% (better)−325%
Growth
Revenue growth (TTM)22.6%23.0% (better)
Revenue growth, 5Y average–17.3%
Net income growth (TTM)64.6%241% (better)
EPS growth (TTM)62.2%500% (better)
EPS growth, 5Y average–39.8%
Profitability
Gross margin–74.6%
Operating margin44.9% (better)6.0%
Net margin54.8% (better)7.9%
FCF margin58.5% (better)20.1%
Return on equity20.1% (better)7.2%
Return on invested capital45.3% (better)7.2%
Financial health
Debt / equity0.000.00
Interest coverage–28.5×
Current ratio8.32 (better)5.04
Altman Z-score38.98 (better)13.47
Piotroski F-score67 (better)
Dividends and buybacks
Buyback yield–−0.24%
Shareholder yield0.00% (better)−0.24%
Ownership
Held by institutions102%108%
Held by insiders17.1%1.3%
Insider net buying, 12 months−$105M−$13.0M (better)
Short interest, % of float12.4%10.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.